CCL

Összesen 5 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM123185
035-os BibID:(Scopus)85201523429 (WoS)001293598800001
Első szerző:Fésüs Adina (gyógyszerész)
Cím:The effect of the antibiotic stewardship program (ASP) on community-acquired pneumonia (CAP) : a before-after study / Adina Fésüs, Phiona Baluku, Éva Sipos, Sándor Somodi, Enikő Berczi-Kun, István Lekli, Ildikó Bácskay, Ria Benkő, Attila Vaskó
Dátum:2024
Megjegyzések:Background: Community-acquired pneumonia (CAP) is one of the leading causes of death worldwide. Antibiotic stewardship program (ASP) has been implemented to improve rational and responsible antibiotic use by encouraging guideline adherence. Objective: This retrospective observational before?after study aimed to evaluate whether the ASP may improve guideline adherence, antibiotic exposure, and clinical outcomes in patients hospitalized due to CAP in Hungary. Methods: The study was conducted at a pulmonology department of a tertiary care medical center in Hungary. The ASP implementation consisted of written and published guidelines available to all professionals, continuous supervision, and counseling services on antibiotic therapies at an individual level, with the aim of ensuring compliance with CAP guidelines. Overall guideline adherence (agent selection, route of administration, and dose), clinical outcomes (length of stay and 30-day mortality), antibiotic exposure, and direct costs were compared between the two periods. Fisher's exact test and t-test were applied to compare categorical and continuous variables, respectively. P-values below 0.05 were defined as significant. Results: Significant improvement in overall CAP guideline adherence (30.2%), sequential therapy (10.5%), and a significant reduction in the total duration of antibiotic therapy (13.5%) were observed. Guideline non-adherent combination therapies with metronidazole decreased significantly by 28.1%. Antibiotic exposure decreased by 7.2%, leading to a significant decrease in direct costs (23.6%). Moreover, the ASP had benefits for clinical outcomes, and length of stay decreased by 13.5%. Conclusion: The ASP may play an important role in optimizing empirical antibiotic therapy in CAP having a sustained long-term effect.
Tárgyszavak:Orvostudományok Gyógyszerészeti tudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
community-acquired pneumonia
hospitalized patients
empirical antibiotic therapy
antibiotic stewardship
clinical outcomes
intervention
Megjelenés:Frontiers in Pharmacology. - 15 (2024), p. 1-12. -
További szerzők:Baluku, Phiona Sipos Éva (1989-) (gyógyszerész) Somodi Sándor (1977-) (belgyógyász) Berczi-Kun Enikő Lekli István (1981-) (gyógyszerész) Bácskay Ildikó (1969-) (gyógyszerész, gyógyszertechnológus) Benkő Ria Vaskó Attila (1976-) (tüdőgyógyász)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM075559
035-os BibID:(scopus)85051666187 (wos)000441409800001
Első szerző:Gharbia, Sami
Cím:Enhancement of Silymarin Anti-fibrotic Effects by Complexation With Hydroxypropyl (HPBCD) and Randomly Methylated (RAMEB) β-Cyclodextrins in a Mouse Model of Liver Fibrosis / Sami Gharbia, Cornel Balta, Hildegard Herman, Marcel Rosu, Judit Váradi, Ildikó Bácskay, Miklós Vecsernyés, Szilvia Gyöngyösi, Ferenc Fenyvesi, Sorina N. Voicu, Miruna S. Stan, Roxana E. Cristian, Anca Dinischiotu, Anca Hermenean
Dátum:2018
ISSN:1663-9812
Tárgyszavak:Orvostudományok Gyógyszerészeti tudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Frontiers in Pharmacology. - 9 (2018), p. 1-18. -
További szerzők:Balta, Cornel Herman, Hildegard Rosu, Marcel Váradi Judit (1973-) (gyógyszerész, gyógyszertechnológus) Bácskay Ildikó (1969-) (gyógyszerész, gyógyszertechnológus) Vecsernyés Miklós (1959-) (gyógyszertechnológus, endokrinológus) Gyöngyösi Szilvia (1983-) (anyagmérnök, gépészmérnök) Fenyvesi Ferenc (1977-) (gyógyszerész, gyógyszertechnológus) Voicu, Sorina N. Stan, Miruna Cristian, Roxana E. Dinischiotu, Anca Hermenean, Anca
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM122638
035-os BibID:(scopus)85200837955 (wos)001285058800001
Első szerző:Girgis, Michael Magdy Fahmy (Gyógyszerész)
Cím:Seriousness and outcomes of reported adverse drug reactions in old and new antiseizure medications : a pharmacovigilance study using EudraVigilance database / Michael Magdy Fahmy Girgis, Gergely Farkasinszky, Klára Fekete, István Fekete, Miklos Vecsernyes, Ildikó Bácskay, László Horváth
Dátum:2024
Megjegyzések:Introduction Epilepsy is a widespread disease requiring long-term drug treatment. The aim of this study was to collect information on reported suspected adverse drug reactions (sADRs) of antiseizure medications (ASMs) and study their seriousness and outcomes in various system organ classifications (SOCs). We intended to compare old and new ASMs' ADRs. Methods Using EudraVigilance (EV) database, we extracted line listings of reported sADRs with different ASMs over the period from January 2012 to December 2021. The list of ASMs was compiled according to the Anatomical therapeutic chemical classification system. The Medical Dictionary for Regulatory Activities version 24.0 was used for determining the SOCs of individual reported preferred terms (PTs) sADRs. In addition, we calculated the Reporting Odds Ratio (ROR), 95% confidence interval (95% CI), p-value (statistically significant if p<0.05) and chi-square statistics. Results A total of 276,694 reports were contained in the exported line listings which included 1,051,142 individual sADRs reported as PTs such as seizure (3.49%), drug ineffective (2.46%), somnolence (1.32%), dizziness (1.29%) and represented four SOCs: nervous system disorders (19.26%), general disorders and administration site conditions (14.39%), psychiatric disorders (11.29%) and injury, poisoning and procedural complications (9.79). Among patients, the age group between 18 and 64 years had the highest percentage (52.40%), followed by those aged over 64 years (18.75%). Of all the reported PTs, 882,706 (83.98%) had reported seriousness. Old ASMs had a significant positive association with ♭caused/prolonged hospitalisation', ♭congenital anomaly', ♭disabling', ♭life threatening' and ♭results in death', while new ASMS with ♭other medically important condition'. There were 386 (0.04%) PTs related to Sudden Unexpected Death in Epilepsy (SUDEP). Conclusion In our study, we examined 10 years' reported sADRs of ASMs in the EV international database. The majority of PTs were serious. Old ASMs were generally more commonly associated with undesired outcomes and seriousness. Considering their expected seriousness and outcomes, the safety profile of the different ASMs, can play a cardinal role in the selection of ASMs.
Tárgyszavak:Orvostudományok Gyógyszerészeti tudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Epilepsy
Seizure
treatment
Antiseizure medications (ASMs)
Adverse events
Adverse drug reactions
Pharmacovigilance
EudraVigilance (EV)
System Organ Classifications (SOCs)
Outcomes
Seriousness
Sudden Unexpected Death in Epilepsy (SUDEP)
Megjelenés:Pharmacology Pharmacoepidemiology. - 15 (2024), p. 1-17. -
További szerzők:Farkasinszky Gergely (1990-) (gyógyszerész) Fekete Klára (1978-) (neurológus) Fekete István (1951-) (neurológus, pszichiáter) Vecsernyés Miklós (1959-) (gyógyszertechnológus, endokrinológus) Bácskay Ildikó (1969-) (gyógyszerész, gyógyszertechnológus) Horváth László (1973-) (gyógyszerész)
Pályázati támogatás:TKP2021-EGA-18
Egyéb
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM113471
035-os BibID:(WoS)001038394500001 (Scopus)85166012287
Első szerző:Horváth László (gyógyszerész)
Cím:Six years' experience and trends of serum 25-hydroxy vitamin D concentration and the effect of vitamin D3 consumption on these trends / Horváth László, Mirani Sara, Girgis Michael Magdy Fahmy, Rácz Szilvia, Bácskay Ildikó, Bhattoa Harjit Pal, Tóth Béla E.
Dátum:2023
ISSN:1663-9812
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Frontiers in Pharmacology. - 14 (2023), p. 1-16. -
További szerzők:Mirani, Sara (1978-) (Phd hallgató) Girgis, Michael Magdy Fahmy (1991-) (Gyógyszerész) Rácz Szilvia (1989-) (molekulársi biológus) Bácskay Ildikó (1969-) (gyógyszerész, gyógyszertechnológus) Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Tóth E. Béla (1960-) (orvos)
Pályázati támogatás:GINOP-2.3.1-20-2020-00004
GINOP
GINOP-2.3.4-15.2020.00008
GINOP
TPK2021-EGA-18
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM117746
035-os BibID:(Scopus)85181199885 (WoS)001133248900001
Első szerző:Trotta, Maria Consiglia
Cím:Chrysin-based supramolecular cyclodextrin-calixarene drug delivery system : a novel approach for attenuating cardiac fibrosis in chronic diabetes / Maria Consiglia Trotta, Hildegard Herman, Alina Ciceu, Bianca Mladin, Marcel Rosu, Caterina Claudia Lepre, Marina Russo, Ildikó Bácskay, Ferenc Fenyvesi, Raffaele Marfella, Anca Hermenean, Cornel Balta, Michele D'Amico
Dátum:2023
ISSN:1663-9812
Megjegyzések:Introduction: Cardiac fibrosis is strongly induced by diabetic conditions. Both chrysin (CHR) and calixarene OTX008, a specific inhibitor of galectin 1 (Gal-1), seem able to reduce transforming growth factor beta (TGF-?)/SMAD pro-fibrotic pathways, but their use is limited to their low solubility. Therefore, we formulated a dual-action supramolecular system, combining CHR with sulfobutylated ?-cyclodextrin (SBECD) and OTX008 (SBECD + OTX + CHR). Here we aimed to test the anti-fibrotic effects of SBECD + OTX + CHR in hyperglycemic H9c2 cardiomyocytes and in a mouse model of chronic diabetes. Methods: H9c2 cardiomyocytes were exposed to normal (NG, 5.5 mM) or high glucose (HG, 33 mM) for 48 h, then treated with SBECD + OTX + CHR (containing OTX008 0.75?1.25?2.5 ?M) or the single compounds for 6 days. TGF-?/SMAD pathways, Mitogen-Activated Protein Kinases (MAPKs) and Gal-1 levels were assayed by Enzyme-Linked Immunosorbent Assays (ELISAs) or Real-Time Quantitative Reverse Transcription Polymerase chain reaction (qRT-PCR). Adult CD1 male mice received a single intraperitoneal (i.p.) administration of streptozotocin (STZ) at a dosage of 102 mg/kg body weight. From the second week of diabetes, mice received 2 times/week the following i.p. treatments: OTX (5 mg/kg)-SBECD; OTX (5 mg/kg)-SBECD-CHR, SBECD-CHR, SBECD. After a 22-week period of diabetes, mice were euthanized and cardiac tissue used for tissue staining, ELISA, qRT-PCR aimed to analyse TGF-?/SMAD, extracellular matrix (ECM) components and Gal-1. Results: In H9c2 cells exposed to HG, SBECD + OTX + CHR significantly ameliorated the damaged morphology and reduced TGF-?1, its receptors (TGF?R1 and TGF?R2), SMAD2/4, MAPKs and Gal-1. Accordingly, these markers were reduced also in cardiac tissue from chronic diabetes, in which an amelioration of cardiac remodeling and ECM was evident. In both settings, SBECD + OTX + CHR was the most effective treatment compared to the other ones. Conclusion: The CHR-based supramolecular SBECD-calixarene drug delivery system, by enhancing the solubility and the bioavailability of both CHR and calixarene OTX008, and by combining their effects, showed a strong anti-fibrotic activity in rat cardiomyocytes and in cardiac tissue from mice with chronic diabetes. Also an improved cardiac tissue remodeling was evident. Therefore, new drug delivery system, which could be considered as a novel putative therapeutic strategy for the treatment of diabetes-induced cardiac fibrosis.
Tárgyszavak:Orvostudományok Gyógyszerészeti tudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
chrysin
cyclodextrin
calixarene
drug delivery system
cardiac fibrosis
chronic diabetes
Megjelenés:Frontiers in Pharmacology. - 14 (2023), p. 1-17. -
További szerzők:Herman, Hildegard Ciceu, Alina Mladin, Bianca Rosu, Marcel Lepre, Caterina Claudia Russo, Marina Bácskay Ildikó (1969-) (gyógyszerész, gyógyszertechnológus) Fenyvesi Ferenc (1977-) (gyógyszerész, gyógyszertechnológus) Marfella, Raffaele Hermenean, Anca Balta, Cornel D'Amico, Michele
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v10.11.18-SNAPSHOT © 2024 Monguz kft. Minden jog fenntartva.